The association of genetic polymorphisms and P2Y12 inhibitors in regards to efficacy for patients with ischemic stroke or transient ischemic attack (TIA) remains controversial. Drs. Deepak Bhatt of Brigham and Women’s Hospital and Natalie Kreitzer of the University of Cincinnati discuss key perspectives from a neurocritical, emergency medicine, and stroke perspective related to this important area of medicine.